Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells

Cancer Research

Volumn 75, Issue 17, 2015, Pages 3456-3465

  Bodogai, Monica ^a   Moritoh, Kanako ^a   Lee Chang, Catalina ^a   Hollander, Christine M ^b   Sherman Baust, Cheryl A ^a   Wersto, Robert P ^a   Araki, Yoshihiko ^c   Miyoshi, Ichiro ^d   Yang, Li ^b   Trinchieri, Giorgio ^e   Biragyn, Arya ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL LOSS; CELL POPULATION; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; METASTASIS; MONOCYTE; MOUSE; MURINE MODEL; MYELOID DERIVED SUPPRESSIVE CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MODEL; ANIMAL; BONE MARROW CELL; CELL LINEAGE; DISEASE MODEL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES, REGULATORY; CELL LINEAGE; DISEASE MODELS, ANIMAL; GRANULOCYTES; HUMANS; IMMUNOSUPPRESSION; MELANOMA, EXPERIMENTAL; MICE; MONOCYTES; MYELOID CELLS; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 84942920079     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3077     Document Type: Article

References (40)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
2. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30.
3. Serafini P, De SC, Marigo I, Cingarlini S, Dolcetti L, Gallina G, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72.
4. Movahedi K, GuilliamsM, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloidderived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008;111:4233-44.
5. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets ofmyeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
6. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-8.
7. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45.
8. Kallberg E, Stenstrom M, Liberg D, Ivars F, Leanderson T. CD11b+Ly6C++Ly6G- cells show distinct function in mice with chronic inflammation or tumor burden. BMC Immunol 2012;13:69.
9. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-54.
10. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4- induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003;170:270-8.
11. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116:2777-90.
12. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloidderived suppressor cells. J Immunol 2009;182:5693-701.
13. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284-90.
14. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-70.
15. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009;69:5996-6004.
16. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 2011;71: 3505-15.
17. Bodogai M, Lee Chang C, Wejksza K, Lai J, MerinoM, Wersto RP, et al. Anti- CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res 2013;73:2127-38.
18. Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel R, et al. Inhibition of breast cancer metastasis by resveratrolmediated inactivation of tumor-evoked regulatory B cells. J Immunol 2013;191:4141-51.
19. Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, et al. Cancer-produced metabolites of 5-lipoxygenase induce tumorevoked regulatory B cells via peroxisome proliferator-activated receptor alpha. J Immunol 2013;190:2575-84.
20. Sherman-Baust CA, Kuhn E, Valle BL, Shih Ie M, Kurman RJ, Wang TL, et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014;233:228-37.
21. Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, et al. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discov 2013; 3:936-51.
22. Cai H, Dikalov S, Griendling KK, Harrison DG. Detection of reactive oxygen species and nitric oxide in vascular cells and tissues: comparison of sensitivity and specificity. Methods Mol Med 2007;139:293-311.
23. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth- Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
24. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4: 627-30.
25. Bao Y, Cao X. The immune potential and immunopathology of cytokineproducing B cell subsets: A comprehensive review. J Autoimmun 2014; 55:10-23.
26. Reyes JL, Wang A, Fernando MR, Graepel R, Leung G, van Rooijen N, et al. Splenic B cells from Hymenolepis diminuta-infected mice ameliorate colitis independent of T cells and via cooperation with macrophages. J Immunol 2015;194:364-78.
27. Taylor AW. Review of the activation of TGF-beta in immunity. J Leukoc Biol 2009;85:29-33.
28. DuPre SA, Redelman D, Hunter KW Jr The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007;88:351-60.
29. Michaeloudes C, Sukkar MB, Khorasani NM, Bhavsar PK, Chung KF. TGFbeta regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells.AmJ Physiol Lung CellMol Physiol 2011;300: L295-304.
30. De Bleser PJ, Xu G, Rombouts K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem 1999;274: 33881-7.
31. Ayache N, Boumediene K, Mathy-Hartert M, Reginster JY, Henrotin Y, Pujol JP. Expression of TGF-betas and their receptors is differentially modulated by reactive oxygen species and nitric oxide in human articular chondrocytes. Osteoarthritis Cartilage 2002;10:344-52.
32. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125:451-8.
33. Brodt P, Gordon J. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978; 121:359-62.
34. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-23.
35. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cellderived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010;464:302-5.
36. Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res 2013;73:2468-79.
37. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7.
38. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237: 264-83.
39. Wong SC, Puaux AL, Chittezhath M, Shalova I, Kajiji TS, Wang X, et al. Macrophage polarization to a unique phenotype driven by B cells. European J Immunol 2010;40:2296-307.
40. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014;25:809-21.